Febrile pleuropericarditis, a potentially life-threatening adverse event of balsalazide – case report and literature review of the side effects of 5-aminosalicylates

References

• Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977;2:892-5
   PubMed Web of Science ®Google Scholar
• Campieri M, De Franchis R, Bianchi Porro G, et al. Mesalazine (5-aminosalicylic acid) suppositories in the treatment of ulcerative proctitis or distal proctosigmoiditis. A randomized controlled trial. Scand J Gastroenterol 1990;25:663-8
   PubMed Web of Science ®Google Scholar
• Marshall JK, Thabane M, Steinhart AH, et al. Rectal 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2012;11:CD004118
   Google Scholar
• Marshall JK, Thabane M, Steinhart AH, et al. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2010;(1):CD004115
   Google Scholar
• Kam L, Cohen H, Dooley C, et al. A comparison of mesalamine suspension enema and oral sulfasalazine for treatment of active distal ulcerative colitis in adults. Am J Gastroenterol 1996;91:1338-42
   PubMed Web of Science ®Google Scholar
• Rao SS, Cann PA, Holdsworth CD. Clinical experience of the tolerance of mesalazine and olsalazine in patients intolerant of sulphasalazine. Scand J Gastroenterol 1987;22:332-6
   PubMed Web of Science ®Google Scholar
• Kung SJ, Choudhary C, McGeady SJ, Cohn JR. Lack of cross-reactivity between 5-aminosalicylic acid-based drugs: a case report and review of the literature. Ann Allergy Asthma Immunol 2006;97:284-7
   PubMed Web of Science ®Google Scholar
• Sandberg-Gertzen H, Jarnerot G, Tysk C. Long-term treatment with olsalazine for ulcerative colitis: safety and relapse prevention: A follow-up study. Scand J Gastroenterol Suppl 1988;148:48-50
   PubMedGoogle Scholar
• Firwana BM, Hasan R, Chalhoub W, et al. Nephrotic syndrome after treatment of Crohn’s disease with mesalamine: case report and literature review. Avicenna J Med 2012;2:9-11
   PubMedGoogle Scholar
• Ishikawa N, Imamura T, Nakajima K, et al. Acute pericarditis associated with 5-aminosalicylic acid (5-ASA) treatment for severe active ulcerative colitis. Intern Med 2001;40:901-4
   PubMed Web of Science ®Google Scholar
• Stelts S, Taylor MH, Nappi J, Van Bakel AB. Mesalamine-associated hypersensitivity myocarditis in ulcerative colitis. Ann Pharmacother 2008;42:904-5
   PubMed Web of Science ®Google Scholar
• Honeybourne D. Mesalazine toxicity. BMJ 1994;308:533-4
   PubMed Web of Science ®Google Scholar
• Slim R, Amara J, Nasnas R, et al. Isolated fever induced by mesalamine treatment. World J Gastroenterol 2013;19:1147-9
   PubMed Web of Science ®Google Scholar
• Gonzalo MA, Alcalde MM, Garcia JM, et al. Desensitization after fever induced by mesalazine. Allergy 1999;54:1224-5
   PubMed Web of Science ®Google Scholar
• Patil SA, Moss AC. Balsalazide disodium for the treatment of ulcerative colitis. Expert Rev Gastroenterol Hepatol 2008;2:177-84
   PubMedGoogle Scholar
• Quiros JA, Heyman MB, Pohl JF, et al. Safety, efficacy, and pharmacokinetics of balsalazide in pediatric patients with mild-to-moderate active ulcerative colitis: results of a randomized, double-blind study. J Pediatr Gastroenterol Nutr 2009;49:571-9
   PubMed Web of Science ®Google Scholar
• Mansfield JC, Giaffer MH, Cann PA, et al. A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis. Aliment Pharmacol Ther 2002;16:69-77
   PubMed Web of Science ®Google Scholar
• Green JR, Mansfield JC, Gibson JA, et al. A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis. Aliment Pharmacol Ther 2002;16:61-8
   PubMed Web of Science ®Google Scholar
• Giaffer MH, O’Brien CJ, Holdsworth CD. Clinical tolerance to three 5-aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine. Aliment Pharmacol Ther 1992;6:51-9
   PubMed Web of Science ®Google Scholar
• Muijsers RB, Goa KL. Balsalazide: a review of its therapeutic use in mild-to-moderate ulcerative colitis. Drugs 2002;62:1689-705
   PubMed Web of Science ®Google Scholar
• Schroeder KW. Role of mesalazine in acute and long-term treatment of ulcerative colitis and its complications. Scand J Gastroenterol 2002;(Suppl):42-7
   Google Scholar
• Ragunath K, Williams JG. Review article: balsalazide therapy in ulcerative colitis. Aliment Pharmacol Ther 2001;15:1549-54
   PubMed Web of Science ®Google Scholar
• Robertson E, Austin D, Jamieson N, Hogg KJ. Balsalazide-induced myocarditis. Int J Cardiol 2008;130:e121-2
   PubMed Web of Science ®Google Scholar
• Kang SM, Jang YR, Yoon HH, et al. A case of balsalazide-induced limited form of granulomatosis with polyangiitis with bronchiolitis obliterans organizing pneumonia-like variant in ulcerative colitis. Tuberc Respir Dis (Seoul) 2012;72:323-7
   PubMedGoogle Scholar
• Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol 2006;12:4819-31
   PubMed Web of Science ®Google Scholar
• Larsen S, Bendtzen K, Nielsen OH. Extraintestinal manifestations of inflammatory bowel disease: epidemiology, diagnosis, and management. Ann Med 2010;42:97-114
   PubMed Web of Science ®Google Scholar
• Agrawal D, Rukkannagari S, Kethu S. Pathogenesis and clinical approach to extraintestinal manifestations of inflammatory bowel disease. Minerva Gastroenterol Dietol 2007;53:233-48
   PubMedGoogle Scholar
• Trikudanathan G, Venkatesh PG, Navaneethan U. Diagnosis and therapeutic management of extra-intestinal manifestations of inflammatory bowel disease. Drugs 2012;72:2333-49
   PubMed Web of Science ®Google Scholar
• Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 2001;96:1116-22
   PubMed Web of Science ®Google Scholar
• Das KM. Relationship of extraintestinal involvements in inflammatory bowel disease: new insights into autoimmune pathogenesis. Dig Dis Sci 1999;44:1-13
   PubMed Web of Science ®Google Scholar
• Storch I, Sachar D, Katz S. Pulmonary manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2003;9:104-15
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay D, Nasr K, Grossman BJ, Kirsner JB. Pericarditis associated with inflammatory bowel disease. JAMA 1970;211:1540-2
   PubMedGoogle Scholar
• Breitenstein RA, Salel AF, Watson DW. Letter: chronic inflammatory bowel disease: Acute pericarditis and pericardial tamponade. Ann Intern Med 1974;81:406
   PubMed Web of Science ®Google Scholar
• Thompson DG, Lennard-Jones JE, Swarbrick ET, Bown R. Pericarditis and inflammatory bowel disease. Q J Med 1979;48:93-7
   PubMedGoogle Scholar
• Faller M, Gasser B, Massard G, et al. Pulmonary migratory infiltrates and pachypleuritis in a patient with Crohn’s disease. Respiration 2000;67:459-63
   PubMed Web of Science ®Google Scholar
• Patwardhan RV, Heilpern RJ, Brewster AC, Darrah JJ. Pleuropericarditis: an extraintestinal complication of inflammatory bowel disease. Report of three cases and review of literature. Arch Intern Med 1983;143:94-6
   PubMedGoogle Scholar
• Orii S, Chiba T, Nakadate I, et al. Pleuropericarditis and disseminated intravascular coagulation in ulcerative colitis. J Clin Gastroenterol 2001;32:251-4
   PubMed Web of Science ®Google Scholar
• Stajer D, Gorjup V. Myopericarditis, pleuritis and deep venous thrombosis in ulcerative colitis masquerading as pulmonary embolism. Intensive Care Med 1996;22:1134-5
   PubMed Web of Science ®Google Scholar
• Camus P, Piard F, Ashcroft T, et al. The lung in inflammatory bowel disease. Medicine (Baltimore) 1993;72:151-83
   PubMed Web of Science ®Google Scholar
• Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology 2005;129:827-36
   PubMed Web of Science ®Google Scholar
• Taurog JD, Richardson JA, Croft JT, et al. The germfree state prevents development of gut and joint inflammatory disease in hla-b27 transgenic rats. J Exp Med 1994;180:2359-64
   PubMed Web of Science ®Google Scholar
• Contractor NV, Bassiri H, Reya T, et al. Lymphoid hyperplasia, autoimmunity, and compromised intestinal intraepithelial lymphocyte development in colitis-free gnotobiotic il-2-deficient mice. J Immunol 1998;160:385-94
   PubMed Web of Science ®Google Scholar
• Mohammed AR, Babu S. Serositis and inflammatory bowel disease. Br J Hosp Med (Lond) 2008;69:296-7
   PubMed Web of Science ®Google Scholar
• Abu-Hijleh M, Evans S, Aswad B. Pleuropericarditis in a patient with inflammatory bowel disease: a case presentation and review of the literature. Lung 2010;188:505-10
   PubMed Web of Science ®Google Scholar
• Black H, Mendoza M, Murin S. Thoracic manifestations of inflammatory bowel disease. Chest 2007;131:524-32
   PubMed Web of Science ®Google Scholar
• Feagan BG, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2012;10:CD000544
   Google Scholar
• Tong JL, Huang ML, Xu XT, et al. Once-daily versus multiple-daily mesalamine for patients with ulcerative colitis: a meta-analysis. J Dig Dis 2012;13:200-7
   PubMed Web of Science ®Google Scholar
• Flourie B, Hagege H, Tucat G, et al. Randomised clinical trial: once- vs. Twice-daily prolonged-release mesalazine for active ulcerative colitis. Aliment Pharmacol Ther 2013;37:767-75
   PubMed Web of Science ®Google Scholar
• Loftus EV. Jr., Kane SV, Bjorkman D. Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2004;19:179-89
   PubMed Web of Science ®Google Scholar
• Marteau P, Nelet F, Le Lu M, Devaux C. Adverse events in patients treated with 5-aminosalicyclic acid: 1993-1994 pharmacovigilance report for Pentasa in France. Aliment Pharmacol Ther 1996;10:949-56
   PubMed Web of Science ®Google Scholar
• Schroeder KW. Is mesalamine safe? Gastroenterol Hepatol (NY) 2007;3:878-9
   PubMedGoogle Scholar
• Jenss H, Becker EW, Weber P. Pericardial effusion during treatment with 5-aminosalicylic acid in a patient with Crohn’s disease. Am J Gastroenterol 1990;85:332-3
   PubMed Web of Science ®Google Scholar
• Kaiser GC, Milov DE, Erhart NA, Bailey DJ. Massive pericardial effusion in a child following the administration of mesalamine. J Pediatr Gastroenterol Nutr 1997;25:435-8
   PubMed Web of Science ®Google Scholar
• Doganay L, Akinci B, Pekel N, et al. Mesalazine-induced myopericarditis in a patient with ulcerative colitis. Int J Colorectal Dis 2006;21:199-200
   PubMed Web of Science ®Google Scholar
• Iaquinto G, Sorrentini I, Petillo FE, Berardesca G. Pleuropericarditis in a patient with ulcerative colitis in longstanding 5-aminosalicylic acid therapy. Ital J Gastroenterol 1994;26:145-7
   PubMedGoogle Scholar
• Gujral N, Friedenberg F, Friedenberg J, et al. Pleuropericarditis related to the use of mesalamine. Dig Dis Sci 1996;41:624-6
   PubMed Web of Science ®Google Scholar
• Waite RA, Malinowski JM. Possible mesalamine-induced pericarditis: case report and literature review. Pharmacotherapy 2002;22:391-4
   PubMed Web of Science ®Google Scholar
• Sentongo TA, Piccoli DA. Recurrent pericarditis due to mesalamine hypersensitivity: a pediatric case report and review of the literature. J Pediatr Gastroenterol Nutr 1998;27:344-7
   PubMed Web of Science ®Google Scholar
• Perez-Colon E, Dadlani GH, Wilmot I, Miller M. Mesalamine-induced myocarditis and coronary vasculitis in a pediatric ulcerative colitis patient: a case report. Case Rep Pediatr 2011;2011:524364
   PubMedGoogle Scholar
• Merceron O, Bailly C, Khalil A, et al. Mesalamine-induced myocarditis. Cardiol Res Pract 2010. [Epub ahead of print]
   PubMedGoogle Scholar
• Garcia-Ferrer L, Estornell J, Palanca V. Myocarditis by mesalazine with cardiac magnetic resonance imaging. Eur Heart J 2009;30:1015
   PubMed Web of Science ®Google Scholar
• Bernal-Sprekelsen JC, de las Marinas MD, Salvador A, et al. Recurrent pericarditis in a patient with ulcerative proctitis due to mesalazine suppositories. Int J Colorectal Dis 2010;25:1143-4
   PubMed Web of Science ®Google Scholar
• Kristensen KS, Hoegholm A, Bohr L, Friis S. Fatal myocarditis associated with mesalazine. Lancet 1990;335:605
   PubMed Web of Science ®Google Scholar
• Agnholt J, Sorensen HT, Rasmussen SN, et al. Cardiac hypersensitivity to 5-aminosalicylic acid. Lancet 1989;1:1135
   PubMed Web of Science ®Google Scholar
• Pent MT, Ganapathy S, Holdsworth CD, Channer KC. Mesalazine induced lupus-like syndrome. BMJ 1992;305:159
   PubMed Web of Science ®Google Scholar
• Sposato B, Allegri MP, Riccardi MP, et al. Mesalazine-induced multi-organ hypersensitivity. Clin Drug Investig 2010;30:413-17
   PubMed Web of Science ®Google Scholar
• Miner P, Hanauer S, Robinson M, et al. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa uc maintenance study group. Dig Dis Sci 1995;40:296-304
   PubMed Web of Science ®Google Scholar
• Baker DE, Kane S. The short- and long-term safety of 5-aminosalicylate products in the treatment of ulcerative colitis. Rev Gastroenterol Disord 2004;4:86-91
   PubMedGoogle Scholar
• Sossai P, Cappellato MG, Stefani S. Can a drug-induced pulmonary hypersensitivity reaction be dose-dependent? A case with mesalamine. Mt Sinai J Med 2001;68:389-95
   PubMedGoogle Scholar
• Fishman A, Elias J, Fishman J, et al. Fishman’s pulmonary disease and disorders. McGraw-Hill Professional, New York, NY; 2008.
   Google Scholar